MedDataX Logo

Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)

NCT ID: NCT04609150

Last Updated: 2020-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-30

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multiple myeloma is a disease that causes increased bone fragility which is often revealed or complicated by vertebral fractures. Invasion of bone marrow by tumor plasma cells leads to bone destruction and reduced fat fraction. The main objective is to assess the correlation between vertebral bone marrow fat fraction and bone fragility represented by a severity score of vertebral fractures. The secondary objective is to assess the correlation with clinical and biological prognostic factors and scores..

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients treated with vertebroplasty will be included during the period of the study, retrospectively or prospectively.

Mains collected data are represented by :

* Bone marrow fat fraction determined by MRI
* Severity score for vertebral fractures
* Clinical prognostic factors
* Biological prognostic factors
* Clinico-biological scores Descriptive statistics and correlation analyses will be performed between the measured parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma Vertebral Fracture

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bone marrow fat Bone fragility Fat quantification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple myeloma patients with vertebral fractures

Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events

Bone marrow fat quantification by MRI

Intervention Type OTHER

Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bone marrow fat quantification by MRI

Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients followed for multiple myelomas in the Lariboisière/Saint-Louis/Fernand-Widal hospital group
* vertebral fractures treated by vertebroplasty from January 2017 to December 2021
* recent clinical and biological data available at the time of imaging and fracture events

Exclusion Criteria

* Factors modifying the bone marrow fat fraction (extensive radiotherapy)
* Lack of recent clinical or biological data compared to imaging examinations
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Valérie BOUSSON, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AP-HP, Lariboisière Hospital, Osteo-Articular, Visceral and Vascular Imaging department

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gregoire ATTANE, MD

Role: CONTACT

Phone: +33 (0)688595952

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gregoire ATTANE, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP200091

Identifier Type: -

Identifier Source: org_study_id